Inhibition of the EGFR increases aspartate abundance in NSCLC cells (Makinoshima et al., 2014), while EGF treatment promotes leucine uptake in prostate cancer cells by upregulating the L-type amino acid transporter 3 (LAT3) through the PI3K/AKT pathway (Zhang et al., 2019). Here, SLC43A1 is linked to prostate carcinoma.